DE10208568A1 - Compound containing creatine, an acid component and / or a complexing agent - Google Patents
Compound containing creatine, an acid component and / or a complexing agentInfo
- Publication number
- DE10208568A1 DE10208568A1 DE10208568A DE10208568A DE10208568A1 DE 10208568 A1 DE10208568 A1 DE 10208568A1 DE 10208568 A DE10208568 A DE 10208568A DE 10208568 A DE10208568 A DE 10208568A DE 10208568 A1 DE10208568 A1 DE 10208568A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- creatine
- acids
- component
- acetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 229960003624 creatine Drugs 0.000 title claims abstract description 58
- 239000006046 creatine Substances 0.000 title claims abstract description 58
- 239000002253 acid Substances 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 239000008139 complexing agent Substances 0.000 title claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000009472 formulation Methods 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 235000005911 diet Nutrition 0.000 claims abstract description 4
- 230000000378 dietary effect Effects 0.000 claims abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 239000003674 animal food additive Substances 0.000 claims abstract description 3
- 239000002537 cosmetic Substances 0.000 claims abstract description 3
- 235000013376 functional food Nutrition 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 56
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 24
- -1 aryl sulfonic acids Chemical class 0.000 claims description 24
- 235000011054 acetic acid Nutrition 0.000 claims description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 18
- 229960000583 acetic acid Drugs 0.000 claims description 17
- 239000011976 maleic acid Substances 0.000 claims description 14
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 7
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 7
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011975 tartaric acid Substances 0.000 claims description 6
- 235000002906 tartaric acid Nutrition 0.000 claims description 6
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 claims description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 5
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 5
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- GTZCVFVGUGFEME-HNQUOIGGSA-N cis-Aconitic acid Natural products OC(=O)C\C(C(O)=O)=C/C(O)=O GTZCVFVGUGFEME-HNQUOIGGSA-N 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 235000011007 phosphoric acid Nutrition 0.000 claims description 4
- 150000003016 phosphoric acids Chemical class 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 4
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 3
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical class O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229960002598 fumaric acid Drugs 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 3
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical compound OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- CEGRHPCDLKAHJD-UHFFFAOYSA-N 1,1,1-propanetricarboxylic acid Chemical compound CCC(C(O)=O)(C(O)=O)C(O)=O CEGRHPCDLKAHJD-UHFFFAOYSA-N 0.000 claims description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 claims description 2
- VYSRZETUSAOIMP-UHFFFAOYSA-N 2-furanacetic acid Chemical compound OC(=O)CC1=CC=CO1 VYSRZETUSAOIMP-UHFFFAOYSA-N 0.000 claims description 2
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 claims description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 2
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 claims description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical class CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 claims description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 2
- 108010087806 Carnosine Proteins 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 2
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 150000008575 L-amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 108010077895 Sarcosine Proteins 0.000 claims description 2
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical class CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940044199 carnosine Drugs 0.000 claims description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 229940013688 formic acid Drugs 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 150000001261 hydroxy acids Chemical class 0.000 claims description 2
- 229960002591 hydroxyproline Drugs 0.000 claims description 2
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 claims description 2
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 claims description 2
- HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 239000006014 omega-3 oil Substances 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 235000000053 special nutrition Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 239000000376 reactant Substances 0.000 abstract description 3
- 239000004090 neuroprotective agent Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 6
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 4
- 229960004826 creatine monohydrate Drugs 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000005592 electrolytic dissociation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 150000007519 polyprotic acids Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- RSDQBPGKMDFRHH-MJVIGCOGSA-N (3s,3as,5ar,9bs)-3,5a,9-trimethyl-3a,4,5,7,8,9b-hexahydro-3h-benzo[g][1]benzofuran-2,6-dione Chemical compound O=C([C@]1(C)CC2)CCC(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 RSDQBPGKMDFRHH-MJVIGCOGSA-N 0.000 description 1
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-BKLSDQPFSA-N 4-hydroxy-L-proline Chemical compound OC1C[NH2+][C@H](C([O-])=O)C1 PMMYEEVYMWASQN-BKLSDQPFSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- RSDQBPGKMDFRHH-UHFFFAOYSA-N Taurin Natural products C1CC2(C)C(=O)CCC(C)=C2C2C1C(C)C(=O)O2 RSDQBPGKMDFRHH-UHFFFAOYSA-N 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- JBGMARMAOJZNSL-UHFFFAOYSA-N heptanoic acid;octanoic acid Chemical compound CCCCCCC(O)=O.CCCCCCCC(O)=O JBGMARMAOJZNSL-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 239000011579 vitamin B4 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Beansprucht werden Verbindungen, bestehend aus Kreatin und einer Säure-Komponente und/oder einem Komplex-Bildner, bei denen das Verhältnis Kreatin zum Reaktionspartner von 1,0 bis 10,0 : 1,0 beträgt und bei der die Nicht-Kreatin-Komponente aus den in der Anspruchsfassung genannten Verbindungs-Gruppen ausgewählt wird. Diese Verbindungen, die vorzugsweise kein organisches Lösemittel enthalten und in festem, pulverförmigem Zustand vorliegen, werden insbesondere mit einem Verfahren hergestellt, bei dem DOLLAR A a¶1¶) Kreatin mit einem Anteil von maximal 20 Gew.-% Wasser bei Temperaturen zwischen 0 und 70 DEG C mit dem Reaktionspartner umgesetzt wird DOLLAR A oder DOLLAR A a¶2¶) Kreatin und der Reaktionspartner mit einem Gesamtwassergehalt von 5 bis 15 Gew.-% bei Temperaturen zwischen 0 und 70 DEG C vermahlen werden DOLLAR A oder DOLLAR A a¶3¶) Kreatin in Gegenwart eines Lösemittels bei Temperaturen zwischen 0 und 70 DEG C mit Reaktionspartner(-Salzen) umgesetzt wird. DOLLAR A Abschließend ist vorgesehen, das entsprechende Lösemittel auf einen Restgehalt von maximal 5 Gew.-% zu entfernen. Schließlich werden noch geeignete Formulierungen beansprucht, für die insbesondere die Verwendung als Nahrungsergänzungsmittel, Futterzusatzmittel, Diätetikum, in Funktional Foods, als Neuroprotektivum sowie im Kosmetikbereich usw. vorgesehen ist.Compounds consisting of creatine and an acid component and / or a complexing agent are claimed, in which the ratio of creatine to the reactant is from 1.0 to 10.0: 1.0 and in which the non-creatine component consists of the connection groups mentioned in the claim version is selected. These compounds, which preferably contain no organic solvent and are in a solid, powdery state, are produced in particular by a process in which DOLLAR A a¶1¶) creatine with a maximum of 20% by weight of water at temperatures between 0 and 70 DEG C is reacted with the reaction partner DOLLAR A or DOLLAR A a¶2¶) creatine and the reaction partner with a total water content of 5 to 15% by weight are ground at temperatures between 0 and 70 DEG C DOLLAR A or DOLLAR A a¶ 3¶) Creatine is reacted with reactants (salts) in the presence of a solvent at temperatures between 0 and 70 ° C. DOLLAR A Finally, it is intended to remove the corresponding solvent to a residual content of at most 5% by weight. Finally, suitable formulations are also claimed, for which in particular the use as a dietary supplement, feed additive, dietetic, in functional foods, as a neuroprotective agent and in the cosmetics sector etc. is provided.
Description
Gegenstand der vorliegenden Erfindung sind eine Verbindung, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex-Bildner, Verfahren zu deren Herstellung, eine die Verbindung enthaltende Formulierung sowie deren Verwendung. The present invention relates to a compound containing Creatine, an acid component and / or a complexing agent, Process for their preparation, one containing the compound Formulation and its use.
Kreatin kommt vor allem im Muskel- und Nervengewebe vor und stellt in Form seines Stoffwechselfolgeproduktes Phosphokreatin eine wichtige Energiereserve des Muskels und des Gehirns dar. Creatine is found primarily in muscle and nerve tissue and provides An important form of its metabolic product phosphocreatine Reserves of muscle and brain.
Im Nerven- und Herzmuskelgewebe scheint Kreatin eine prophylaktische und therapeutische Wirkung bei Ischämien zu besitzen, wie sie z. B. durch Infarktgeschehen oder durch prä- und perinatale Sauerstoffdefizit-Zustände verursacht werden. Creatine appears prophylactic in nerve and cardiac muscle tissue and to have therapeutic effect in ischemia, as z. B. by Infarction events or due to pre- and perinatal oxygen deficit conditions caused.
Kreatin ist seit über 100 Jahren als Muskelsubstanz bekannt, wobei es dem Muskel als Energiequelle dient. Creatine has been known as a muscle substance for over 100 years, but it does Muscle serves as an energy source.
Kreatin stellt als körpereigene Substanz nicht nur ein wertvolles Nahrungsergänzungsmittel dar, sondern besitzt auch wertvolle therapeutische Eigenschaften. In einer Reihe von wissenschaftlichen Arbeiten wurde gezeigt, dass die kontrollierte Einnahme von Kreatin über einen längeren Zeitraum zu einer deutlichen Steigerung der Muskelmasse und Muskelleistung sowie der Kraft und Ausdauer führen kann. Creatine is not just a valuable substance in the body Dietary supplements, but also possesses valuable ones therapeutic properties. In a number of scientific Working has shown that controlled intake of creatine is about a longer period of time for a significant increase in muscle mass and muscle performance as well as strength and endurance.
Ein prophylaktischer, therapeutischer oder diätetischer Einsatz von Kreatin in den unterschiedlichsten Applikationsformen (z. B. oral, intravenös usw.) setzt eine hohe Bioverfügbarkeit und damit eine gute Wasserlöslichkeit voraus. Diese ist jedoch für Kreatin, das als Aminosäure-Derivat in Form eines inneren Salzes vorliegt, zumeist nicht in ausreichendem Maße gegeben, weshalb das Kreatin seine unbestrittenen Vorteile v. a. im Rahmen von Supplementierungen und Therapien meist durch eines seiner physiologisch verträglichen Kreatin-Salze erzielt. A prophylactic, therapeutic or dietary use of creatine in a wide variety of application forms (e.g. oral, intravenous, etc.) sets high bioavailability and thus good water solubility ahead. However, this is for creatine that is in the form of an amino acid derivative of an inner salt is present, usually not to a sufficient extent given why the creatine has its undisputed advantages v. a. in the Framework of supplements and therapies mostly through one of his achieved physiologically acceptable creatine salts.
Kreatin ist aus chemischer Sicht sowohl als Protonenakzeptor auch als Komplexbildner zu betrachten. Mit einem pKb-Wert von 11.02 bei 25°C ist Kreatin eine schwache organische Base. From a chemical point of view, creatine can be seen both as a proton acceptor and as a complexing agent. With a pK b value of 11.02 at 25 ° C, creatine is a weak organic base.
Die Salzbildung von Kreatin mit anderen Verbindungen ist am besten als Proton-Transfer-Reaktion zu bezeichnen. In jeder Säure-Base-Reaktion wird ein Proton übertragen, wobei Protonen abgebende Verbindungen als Säuren und Protonen aufnehmende Verbindungen als Basen definiert sind. The salt formation of creatine with other compounds is best considered To denote proton transfer reaction. In every acid-base reaction transfer a proton, whereby proton donating compounds as Acids and proton accepting compounds are defined as bases.
Bei den Säuren unterscheidet man zwei Hauptklassen: die Brønsted-Säuren, welche Protonen abgeben, und die Lewis Säuren, die als Elektronen-Paar- Akzeptoren dienen (z. B. BCl3). Analog sind Brønsted-Basen Protonen- Akzeptoren und Lewis-Basen Elektronen-Paar-Donatoren (z. B. Ammoniak). Es gibt aber noch weitere Klassifizierungen von Säuren, wobei die wichtigsten mehrbasige Säuren beinhalten, also Säuren, welche mehr als ein Proton abgeben können (z. B. Schwefelsäure, Citronensäure). Im Gegensatz hierzu stehen die mehrbasigen Basen (z. B. Carbonat, Hydrogencarbonat). There are two main classes of acids: the Brønsted acids, which give off protons, and the Lewis acids, which serve as electron pair acceptors (e.g. BCl 3 ). Analogously, Brønsted bases are proton acceptors and Lewis bases are electron pair donors (e.g. ammonia). However, there are other classifications of acids, the most important of which include polybasic acids, i.e. acids that can release more than one proton (e.g. sulfuric acid, citric acid). This is in contrast to the polybasic bases (e.g. carbonate, bicarbonate).
Der pKs-Wert der ersten elektrolytischen Dissoziation einer mehrbasigen Säure ist immer niedriger (z. B. starke Säure) als der der zweiten (in Beziehung zu pKs1 und pKs2). Der Grund hierfür ist, dass die Dissoziation des ersten Proton eine negative Ladung hinterlässt, welche die Dissoziation des zweiten Protons aufgrund der Coulombschen Kraft erschwert (Ladungsanziehung). Das bedeutet, dass die erste elektrolytische Dissoziation vollständig sein muss, bevor die zweite beginnt, so dass man sie als separate Reaktionen ansehen kann. The pK of the first electrolytic dissociation of a polybasic acid is always lower (eg. B. strong acid) than the second (in relation to pK 1 and pK 2). The reason for this is that the dissociation of the first proton leaves a negative charge, which complicates the dissociation of the second proton due to the Coulomb force (charge attraction). This means that the first electrolytic dissociation must be complete before the second begins, so that they can be viewed as separate reactions.
Aus diesen Gründen kann Kreatin mit anderen Komponenten (z. B. Maleinsäure) theoretisch Verbindungen bilden, die sowohl ein Salz als auch eine Komplex- und/oder Anlagerungsverbindung sein können. For these reasons, creatine can be combined with other components (e.g. Maleic acid) theoretically form compounds that are both a salt and can be a complex and / or addition compound.
Im Fall der Monokreatin/Maleinsäure-Verbindung, wie sie aus US 5,973,199 bekannt ist, stellt die Maleinsäure eine starke Säure dar, welche durch ihre erste elektrolytische Dissoziationskonstante (pK1-Wert von 1.94 bei 25°C) gekennzeichnet ist, und Kreatin ist eine schwache organische Base, gekennzeichnet durch einen pKb-Wert von 11,02 bei 25°C. In the case of the monocreatine / maleic acid compound, as is known from US Pat. No. 5,973,199, the maleic acid is a strong acid, which is characterized by its first electrolytic dissociation constant (pK 1 value of 1.94 at 25 ° C.), and creatine is one weak organic base, characterized by a pK b value of 11.02 at 25 ° C.
In Anbetracht der pK-Werte für die fiktive Bildung eines Dikreatin/Maleinsäure-Salzes, welches aus zwei Teilen Kreatin und einem Maleinsäure- Dikation bestünde, würde die Säurestärke des zweiten Protons der Maleinsäure (pK2-Wert von 6,23 bei 25°C) aber nicht ausreichen, um ein weiteres Molekül Kreatin zu protonieren. Deshalb ist in diesem Dokument auch nur das 1 : 1-Salz vorbeschrieben. Considering the pK values for the fictitious formation of a dicreatine / maleic acid salt, which would consist of two parts creatine and a maleic acid dication, the acid strength of the second proton of maleic acid (pK 2 value of 6.23 at 25 ° C ) but not enough to protonate another molecule of creatine. Therefore, only the 1: 1 salt is described in this document.
Aus dem US-Patent 5,973,199 sind u. a. auch isolierte, wasserlösliche Salze von Kreatin und Citronensäure bekannt. Brauseformulierungen, die Kreatincitrat oder physikalische Mischungen aus Kreatin und Citronensäure enthalten, sind aus der Patentschrift US 5,925,378 bekannt. From U.S. Patent 5,973,199 u. a. also isolated, water-soluble salts known from creatine and citric acid. Shower formulations that Creatine citrate or physical mixtures of creatine and citric acid contain are known from the patent US 5,925,378.
Weitere Beispiele für Kreatinsalze sind den Dokumenten DE-OS 197 07 694 (Kreatin-ascorbate), DE-OS 196 53 225 (Kreatin-pyruvate) und DE-PS 199 29 993 (Kreatin-α-Ketoglutarate) zu entnehmen. Further examples of creatine salts are the documents DE-OS 197 07 694 (Creatine ascorbate), DE-OS 196 53 225 (creatine pyruvate) and DE-PS 199 29 993 (Creatine α-ketoglutarate).
Der vorliegenden Erfindung lag die Aufgabe zugrunde, Verbindungen, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex- Bildner bereitzustellen, die physiologisch besonders wertvoll sind, gleichzeitig eine gute Wasserlöslichkeit und eine ausreichende Lagerstabilität besitzen und die in einfacher Weise zugänglich sind. The object of the present invention was to develop compounds containing creatine, an acid component and / or a complex To provide educators who are particularly valuable physiologically, at the same time good water solubility and sufficient Have storage stability and are easily accessible.
Gelöst wurde diese Aufgabe durch eine entsprechende Verbindung, bei
der das Verhältnis der Kreatin-Komponente zur Säure- und/oder Komplex-
Komponente 1,0 bis 10,0 : 1 beträgt und bei der die Nicht-Kreatin-
Komponente ausgewählt wird aus der Reihe
- - racemische, D- und L-Aminosäuren und deren Derivate,
nämlich Alanin, β-Alanin, Arginin, Asparagin, Asparaginsäure, Cystein, Cystin, Glutaminsäure, Glutamin, Glycin, N-Methylglycin, Hippursäure (N-Benzoylglycin), Histidin, Isoleucin, Leucin, Lysin, Methionin, Phenylalanin, Prolin, 4-Hydroxyprolin, Serin, Trytophan, Tyrosin, Valin, Ornithin, 5-Hydroxytryptophan, Pipecolinsäure, Alginsäure, 2-, 3- und 4-Aminobenzoesäure, Taurin, Cholin. - - organische Carbonsäuren und deren Derivate,
nämlich Ameisensäure, Essigsäure, Pantothensäure, Folsäure, Biotin, Arachidonsäure, Carnosin, Fumarsäure, Malonsäure, Maleinsäure, Weinsäure, alpha-Aminobuttersäuren, beta-Aminobuttersäuren und gamma-Aminobuttersäuren, Glutathion, Isocitronensäure, cis- und trans-Aconitsäure, Hydroxycitronensäure, Apfelsäure, Nicotinsäure, Benzoesäure, Oxalsäure, Mesoxalsäure, Oxalessigsäure, Bernsteinsäure, Sorbinsäure, Propantricarbonsäure, Crotonsäure, Itaconsäure, Acrylsäure, Methacrylsäure, Mesaconsäure, Phenylessigsäure, Salicylsäure, 4-Hydroxybenzoesäure, Zimtsäure, Mandelsäure, 2-Furancarbonsäure, Acetessigsäure, Glucuronsäure, Gluconsäure, Glucarsäure, Glycerinsäure, Glykolsäure, Buttersäure, Isobuttersäure, Hexansäure, Heptansäure Octansäure, Decansäure, Undecansäure, Dodecansäure, Tetradecansäure, Palmitinsäure, Stearinsäure, Methacrylsäure, Urocansäure, Pyrrolidonsäure, Glutarsäure, Adipinsäure, Pimelinsäure, Suberinsäure, Azelainsäure, Sebacinsäure, Phthalsäure, Terephthalsäure, 2- und 3-Hydroxybenzoesäure, Milchsäure, unter der Voraussetzung, dass Fumarsäure, Malonsäure, Maleinsäure und Weinsäure > 1 Teil Kreatin enthalten, - - Alkyl- und Arylsulfonsäuren,
- - Ester der Phosphorsäuren,
- - saure Heterocyclen,
- - Polymere,
- - Fettsäuren,
- - anorganische Säuren,
- - racemic, D- and L-amino acids and their derivatives,
namely alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, N-methylglycine, hippuric acid (N-benzoylglycine), histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, 4- Hydroxyproline, serine, trytophan, tyrosine, valine, ornithine, 5-hydroxytryptophan, pipecolic acid, alginic acid, 2-, 3- and 4-aminobenzoic acid, taurine, choline. - - organic carboxylic acids and their derivatives,
namely formic acid, acetic acid, pantothenic acid, folic acid, biotin, arachidonic acid, carnosine, fumaric acid, malonic acid, maleic acid, tartaric acid, alpha-aminobutyric acids, beta-aminobutyric acids and gamma-aminobutyric acids, glutathione, isocitric acid, cis- and trans-aconitic acid, hydroxy acid Nicotinic acid, benzoic acid, oxalic acid, mesoxalic acid, oxaloacetic acid, succinic acid, sorbic acid, propane tricarboxylic acid, crotonic acid, itaconic acid, acrylic acid, methacrylic acid, mesaconic acid, phenylacetic acid, salicylic acid, 4-hydroxybenzoic acid, cinnamic acid, mandelic acid, acetic acid, glucoacetic acid, glucoacetic acid, Glyceric acid, glycolic acid, butyric acid, isobutyric acid, hexanoic acid, heptanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tetradecanoic acid, palmitic acid, stearic acid, methacrylic acid, urocanoic acid, pyrrolidonic acid, glutaric acid, adipic acid, pimelic acid, azainic acid, suberic acid acid, sebacic acid, phthalic acid, terephthalic acid, 2- and 3-hydroxybenzoic acid, lactic acid, provided that fumaric acid, malonic acid, maleic acid and tartaric acid contain> 1 part creatine, - - alkyl and aryl sulfonic acids,
- - esters of phosphoric acids,
- acidic heterocycles,
- - polymers,
- - fatty acids,
- - inorganic acids,
Überraschenderweise hat sich bei den erfindungsgemäßen Kreatin- haltigen Verbindungen gezeigt, dass sie eine extrem gute Lagerstabilität aufweisen, was völlig im Gegensatz zu den bislang bekannten Salzen des Kreatins steht, die sich leicht unter Bildung von Kreatinin zersetzen. Zudem war aufgrund vergleichbarer Verbindungen aus dem Stand der Technik davon auszugehen, dass diese Verbindungen als reine Salze vorliegen, was aber u. a. durch IR-Untersuchungen ebenso ausgeschlossen werden kann wie das Vorliegen einfacher physikalischer Mischungen der Kreatin- Komponente mit der jeweiligen Säure-Komponente bzw. dem Komplex- Bildner. Surprisingly, the creatine according to the invention has containing compounds shown that they have extremely good storage stability have what is completely in contrast to the previously known salts of Creatine stands that easily decompose to form creatinine. moreover was due to comparable connections from the prior art assume that these compounds exist as pure salts, what but u. a. can also be excluded by IR investigations how the existence of simple physical mixtures of creatine Component with the respective acid component or the complex Fine Artists.
Die erfindungsgemäßen Verbindungen zeichnen sich darüber hinaus dadurch aus, dass sie in der Regel frei von organischen Lösemittel-Anteilen sind und auch bei einem maximalen Lösemittel-Gehalt von 0,1 Gew.-% deutlich erhöhte Produktqualitäten aufweisen. The compounds of the invention are also distinguished characterized in that they are usually free of organic solvents and even with a maximum solvent content of 0.1% by weight have significantly increased product qualities.
Vor diesem Hintergrund positiver und nicht vorhersehbarer Verbindungseigenschaften haben sich aus der Vielzahl der beanspruchten Alkylsulfonsäuren Methansulfonsäure oder Trifluormethansulfonsäure ebenso als besonders geeignet erwiesen, wie p-Toluolsulfonsäure und Benzolsulfonsäure oder deren Mischungen als Vertreter der Arylsulfonsäuren. Against this background, more positive and unpredictable Connection properties have emerged from the multitude of claims Alkylsulfonic acids methanesulfonic acid or trifluoromethanesulfonic acid also proven to be particularly suitable, such as p-toluenesulfonic acid and Benzenesulfonic acid or mixtures thereof as representatives of the Arylsulfonic.
Als bevorzugte Ester der Phosphorsäuren sind gemäß vorliegender Erfindung phosphorylierte Zucker und Alkohole, Lecithine, Phosphatidylserin und Phosphatidylcholin anzusehen und als bevorzugte Vertreter der sauren Heterocyclen einer der Reihe Alloxan, Harnsäure, Barbitursäure, Meldrumsäure, Cyanursäure und Parabensäure. As preferred esters of phosphoric acids according to the present Invention phosphorylated sugars and alcohols, lecithins, Consider phosphatidylserine and phosphatidylcholine and as preferred Representative of acidic heterocycles of the series alloxan, uric acid, Barbituric acid, Meldrum's acid, cyanuric acid and parabenic acid.
Xanthan, Cellulose, Polyacrylsäuren, Carboxymethylcellulose und Carrageenane werden erfindungsgemäß als zu bevorzugende Polymere und gesättigte und ungesättigte, verzweigte und unverzweigte Fettsäuren wie z. B. Linolensäure, Linolsäure, Omega-3-Fettsäuren und Phitinsäure als Fettsäuren mit besonders günstigen Eigenschaften angesehen. Aus der nicht minder breiten Gruppe der anorganischen Säure-Komponente, die sich für die beanspruchte Verbindung besonders gut eignen, sind insbesondere Borsäure und Sulfaminsäuren als bevorzugt zu betrachten. Xanthan, cellulose, polyacrylic acids, carboxymethyl cellulose and Carrageenans are preferred polymers according to the invention and saturated and unsaturated, branched and unbranched fatty acids such as B. linolenic acid, linoleic acid, omega-3 fatty acids and phitic acid as Viewed fatty acids with particularly favorable properties. From the no less broad group of the inorganic acid component that are particularly well suited for the claimed connection Boric acid and sulfamic acids in particular are to be regarded as preferred.
Unabhängig vom Verbindungs-Typ der jeweiligen Nicht-Kreatin- Komponente sieht die vorliegende Erfindung insbesondere vor, dass die Verbindung die Kreatin- und die Säure-Komponente und/oder den Komplex-Bildner im Mol-Verhältnis 1,0 bis 10,0 : 1 enthält. Regardless of the connection type of the respective non-creatine Component, the present invention provides in particular that the Compound the creatine and the acid component and / or the Contains complexing agents in a molar ratio of 1.0 to 10.0: 1.
Aufgrund der großen Breite von Verbindungen, die als Nicht-Kreatin- Komponente für die erfindungsgemäße Verbindung in Frage kommen, kann diese sowohl in flüssiger wie auch in fester Form vorgelegt werden, wobei sie im festem und hierbei besonders bevorzugt in pulverförmigem Zustand besonders vorteilhafte Eigenschaften aufweist, insbesondere im Hinblick auf die Handhabbarkeit, den Transport und die Lagerung. Due to the wide range of compounds used as non-creatine Component for the compound according to the invention come into question can be presented in both liquid and solid form, where they are in solid and particularly preferably in powder form Condition has particularly advantageous properties, especially in With regard to manageability, transport and storage.
Neben den Verbindungen selbst beansprucht die vorliegende Erfindung
auch Verfahren zu deren Herstellung, wobei in drei alternativen
Verfahrensschritten entweder
- 1. a1) Kreatin mit einem Anteil von maximal 20 Gew.-% Wasser, insbesondere 10 bis 15 Gew.-% Wasser, bei Temperaturen zwischen 0 und 70°C, insbesondere zwischen 10 und 25°C mit der Säure- Komponente und/oder dem Komplex-Bildner umgesetzt wird,
- 1. a2) Kreatin und die Säure-Komponente und/oder der Komplex-Bildner und/oder deren geeignete Salze mit einem Gesamtwassergehalt von 5 bis 20 Gew.-% bei Temperaturen zwischen 0 und 70°C, insbesondere zwischen 10 und 25°C, ohne Löse- oder Dispergiermittel gemischt werden und dann durch eine Vermahlung in einer Mühle, vorzugsweise in einer Prallmühle, umgesetzt werden,
- 1. a3) Kreatin in wässriger oder alkoholischer Lösung oder in Gegenwart eines nicht mit Wasser mischbaren Lösemittels, vorzugsweise Ethylacetat, bei Temperaturen zwischen 0 und 70°C mit der Säure- Komponente und/oder dem Komplex-Bildner oder deren geeignete Salze umgesetzt wird.
- 1. a 1 ) creatine with a maximum of 20 wt .-% water, in particular 10 to 15 wt .-% water, at temperatures between 0 and 70 ° C, in particular between 10 and 25 ° C with the acid component and / or the complexing agent is implemented,
- 1. a 2 ) creatine and the acid component and / or the complexing agent and / or their suitable salts with a total water content of 5 to 20 wt .-% at temperatures between 0 and 70 ° C, in particular between 10 and 25 ° C, are mixed without solvents or dispersants and then reacted by grinding in a mill, preferably in an impact mill,
- 1. a 3 ) creatine is reacted in aqueous or alcoholic solution or in the presence of a water-immiscible solvent, preferably ethyl acetate, at temperatures between 0 and 70 ° C. with the acid component and / or the complexing agent or their suitable salts ,
Im Anschluss an jede der drei genannten alternativen Verfahrensschritte a1)
bis a3) wird im letzten Verfahrensschritt
- a) abschließend das Wasser oder Lösemittel, vorzugsweise unter Vakuum auf einen Restgehalt von 0,1 bis 20 Gew.-% entfernt.
- a) finally the water or solvent, preferably under vacuum to a residual content of 0.1 to 20 wt .-%.
Typischerweise lässt sich mit dieser Vorgehensweise das Salz einer organischen Säure mit Kreatin herstellen, wie es bspw. auch das 1 : 1-Salz des Kreatincitrats darstellt. Typically, this procedure can be used to salt a Produce organic acid with creatine, such as the 1: 1 salt of creatine citrate.
Neben den Verbindungen selbst sowie dem genannten Herstellungsverfahren beansprucht die vorliegende Erfindung auch stabile, physiologisch verträgliche Formulierungen, die die Salze und/oder Anlagerungs- und/oder Komplexverbindung bestehend aus Kreatin und dem jeweiligen Reaktionspartner enthält, wobei Formulierungen besonders bevorzugt werden, die weitere physiologisch verträgliche und/oder physiologisch wirksame Zusätze und/oder Formulierungshilfsmittel enthalten. In addition to the connections themselves and the above Manufacturing methods, the present invention also claims stable, physiologically acceptable formulations containing the salts and / or Addition and / or complex compound consisting of creatine and contains the respective reactant, with particular formulations are preferred, the further physiologically compatible and / or physiologically active additives and / or formulation auxiliaries contain.
Aus der Reihe der besonders geeigneten physiologisch verträglich und/oder physiologisch wirksamen Zusätze haben sich insbesondere Zucker, Alkohole, Vitamine, Spurenelemente, Aminosäure, Neurotransmitter, Stimulantien sowie Farb- und Aromastoffe als geeignet erwiesen, die jedoch von der Nicht-Kreatin-Komponente verschieden sein müssen. Dies sollten auch Kohlenhydrate, wie z. B. Methylcellulosen, SiO2, Lösevermittler, Aromastoffe, sowie Stearate und andere Trenn- und Konservierungsmittel und Texturantien sein, die als Formulierungshilfsmittel bevorzugt werden. From the series of particularly suitable physiologically compatible and / or physiologically active additives, sugar, alcohols, vitamins, trace elements, amino acids, neurotransmitters, stimulants as well as colorants and flavorings have proven to be suitable, but these differ from the non-creatine component have to. This should include carbohydrates such as As methyl celluloses, SiO 2 , solubilizers, flavorings, as well as stearates and other release agents and preservatives and texturants, which are preferred as formulation auxiliaries.
Schließlich umfasst die vorliegende Erfindung auch noch die Verwendung der erfindungsgemäßen Verbindung als Nahrungsergänzungsmittel, Futterzusatzmittel, Diätetikum, in Functional Foods, zur Sonderernährung sowie zur Steigerung der Ausdauer und Kraft im Sportbereich; aber auch zur Rehabilitation, als Neuroprotektivum, zur Verbesserung der Wundheilung, bei Myopathien und Dystrophien sowie im Kosmetikbereich können die erfindungsgemäßen Verbindungen eingesetzt werden, was die Erfindung ebenfalls berücksichtigt. Finally, the present invention also encompasses the use the compound according to the invention as a food supplement, Feed additives, dietary, in functional foods, for special nutrition as well as to increase endurance and strength in sports; but also for rehabilitation, as a neuroprotective agent, for improving the Wound healing, for myopathies and dystrophies as well as in the cosmetics sector the compounds of the invention can be used, which the Invention also considered.
Mit den vorrangig beanspruchten Verbindungen, bestehend aus Kreatin und dem jeweiligen Reaktionspartner, erhält man ein qualitativ hochstehendes Produkt, das i. d. R. weitgehend frei von organischen Lösemitteln ist, das aufgrund seines geringen Wassergehaltes äußerst lagerstabil ist und das trotz seines ebenfalls möglichen, nicht salzartigen Charakters dennoch wertvolle physiologische Eigenschaften besitzt. With the primarily claimed compounds, consisting of creatine and the respective reaction partner, you get a qualitative high-quality product that i. d. Usually largely free of organic Solvents is extremely due to its low water content is stable in storage, despite its also possible, non-salt-like Character still has valuable physiological properties.
Die nachfolgenden Beispiele verdeutlichen diese Vorteile der erfindungsgemäßen Verbindung. The following examples illustrate these advantages of compound of the invention.
7,46 g (0,05 mol) Kreatin-Monohydrat wurden in 100 ml Methanol vorgelegt,
eine halbe Stunde lang gemischt und daraufhin mit 7,31 g (0,05 mol) L-
Glutamin versetzt. Nach zwei Stunden wurde die Temperatur in der
Reaktionsmischung unter Vakuum und durch dosierte Wärmezufuhr zum
Trocknen auf maximal 60°C erhöht. Auf diese Weise erhielt man 13,80 g
(> 99%) der Kreatin/L-Glutamin-Verbindung.
Schmelzpunkt: 193-194°C; IR (KBr): ν = 3408 (s), 3215 (m), 1628 (s),
1408 (m) cm-1.
7.46 g (0.05 mol) of creatine monohydrate were placed in 100 ml of methanol, mixed for half an hour and then mixed with 7.31 g (0.05 mol) of L-glutamine. After two hours, the temperature in the reaction mixture was raised to a maximum of 60 ° C. under vacuum and by metered supply of heat for drying. In this way, 13.80 g (> 99%) of the creatine / L-glutamine compound were obtained.
Melting point: 193-194 ° C; IR (KBr): ν = 3408 (s), 3215 (m), 1628 (s), 1408 (m) cm -1 .
29,8 g (0,2 mol) Kreatin-Monohydrat wurden in 20 ml Wasser vorgelegt,
eine halbe Stunde lang gemischt und daraufhin mit 11,6 g (0,1 mol)
Maleinsäure versetzt. Nach zwei Stunden wurde die Temperatur in der
Reaktionsmischung unter Vakuum und durch dosierte Wärmezufuhr zum
Trocknen auf maximal 60°C erhöht. Auf diese Weise erhielt man ca. 37,43 g
(> 99%) der Dikreatin/Maleinsäure-Verbindung.
Schmelzpunkt: 169-171°C; IR (KBr): ν = 3351 (s), 1612 (s), 1466 (m) cm-1.
29.8 g (0.2 mol) of creatine monohydrate were placed in 20 ml of water, mixed for half an hour and then mixed with 11.6 g (0.1 mol) of maleic acid. After two hours, the temperature in the reaction mixture was raised to a maximum of 60 ° C. under vacuum and by metered supply of heat for drying. In this way, about 37.43 g (> 99%) of the dicreatine / maleic acid compound were obtained.
Melting point: 169-171 ° C; IR (KBr): ν = 3351 (s), 1612 (s), 1466 (m) cm -1 .
14,9 g (0,1 mol) Kreatin-Monohydrat wurden in 200 ml Methanol vorgelegt,
eine halbe Stunde lang gemischt und daraufhin mit 15,1 g (0,1 mol) L-(+)-
Weinsäure versetzt. Nach zwei Stunden wurde die Temperatur in der
Reaktionsmischung unter Vakuum und durch dosierte Wärmezufuhr zum
Trocknen auf maximal 60°C erhöht. Auf diese Weise erhielt man ca. 40,89 g
(> 99%) der Dikreatin/Weinsäure-Verbindung.
Schmelzpunkt: 137-140°C; IR (KBr): ν = 3337 (s), 1618 (s), 1397 (m) cm-1.
14.9 g (0.1 mol) of creatine monohydrate were placed in 200 ml of methanol, mixed for half an hour and then treated with 15.1 g (0.1 mol) of L - (+) - tartaric acid. After two hours, the temperature in the reaction mixture was raised to a maximum of 60 ° C. under vacuum and by metered supply of heat for drying. In this way, approximately 40.89 g (> 99%) of the dicreatine / tartaric acid compound were obtained.
Melting point: 137-140 ° C; IR (KBr): ν = 3337 (s), 1618 (s), 1397 (m) cm -1 .
0,9 g (0,006 mol) Kreatin-Monohydrat wurden in 60 ml
Chloroform/Methanol (1 : 1) vorgelegt, eine halbe Stunde lang gemischt und daraufhin
mit 5,2 g Phosphatidylserin (Leci PS 90PN) versetzt. Nach zwei Stunden
wurde die Temperatur in der Reaktionsmischung unter Vakuum und durch
dosierte Wärmezufuhr zum Trocknen auf maximal 60°C erhöht. Auf diese
Weise erhielt man ca. 5,93 g (> 99%) der Kreatin/Phosphatidylserin-
Verbindung.
Schmelzpunkt: 147-148°C; IR (KBr): ν = 3422 (s), 2925 (s), 1735 (m),
1637 (m) cm-1.
0.9 g (0.006 mol) of creatine monohydrate were placed in 60 ml of chloroform / methanol (1: 1), mixed for half an hour and then mixed with 5.2 g of phosphatidylserine (Leci PS 90PN). After two hours, the temperature in the reaction mixture was raised to a maximum of 60 ° C. under vacuum and by metered supply of heat for drying. In this way, approximately 5.93 g (> 99%) of the creatine / phosphatidylserine compound were obtained.
Melting point: 147-148 ° C; IR (KBr): ν = 3422 (s), 2925 (s), 1735 (m), 1637 (m) cm -1 .
Bei allen vier genannten Erfindungsbeispielen lag der Kreatinin-Gehalt der Produkte, bestimmt mittels HPLC-Methode, jeweils unter der Nachweisgrenze, also unter 100 ppm. In all four examples of the invention mentioned, the creatinine content was Products determined using the HPLC method, each under the Detection limit, i.e. below 100 ppm.
2 Sportler (männlich; Alter 32 und 33 Jahre) wurden 28 Tage lang mit 5 g einer Dikreatin/Maleinsäure-Verbindung supplementiert. Vor und nach der Supplementation hatten die Sportler hoch-intensive Anstrengungen von kurzer Dauer in Form kontinuierlicher 45 Sekunden Sprungtests zu absolvieren. Im Vergleich zu den Ausgangswerten verbesserten sich beide Sportler im ersten Zeitabschnitt von 15 Sekunden des Tests um 8% (7% bzw. 9%). Im Zeitabschnitt 15 bis 30 Sekunden war eine Verbesserung um 14% (12% bzw. 15%) festzustellen. Die Leistungssteigerung in den letzten 15 Sekunden des Tests lag durchschnittlich bei 4%. 2 athletes (male; ages 32 and 33 years) were exposed to 5 g for 28 days a dicreatine / maleic acid compound. Before and after The athletes had high-intensity supplementation efforts short duration in the form of continuous 45 seconds jump tests complete. Both improved compared to the initial values Athletes in the first period of 15 seconds of the test by 8% (7% or 9%). There was an improvement of 15 to 30 seconds 14% (12% and 15%), respectively. The increase in performance in recent 15 seconds of the test averaged 4%.
Claims (15)
racemische, D- und L-Aminosäuren und deren Derivate,
nämlich Alanin, beta-Alanin, Arginin, Asparagin, Asparaginsäure, Cystein, Cystin, Glutaminsäure, Glutamin, Glycin, N-Methylglycin, Hippursäure (N-Benzoylglycin), Histidin, Isoleucin, Leucin, Lysin, Methionin, Phenylalanin, Prolin, 4-Hydroxyprolin, Serin, Trytophan, Tyrosin, Valin, Ornithin, 5-Hydroxytryptophan, Pipecolinsäure, Alginsäure, 2-, 3- und 4-Aminobenzoesäure, Taurin, Cholin,
organische Carbonsäuren und deren Derivate,
nämlich Ameisensäure, Essigsäure, Pantothensäure, Folsäure, Biotin, Arachidonsäure, Carnosin, Fumarsäure, Malonsäure, Maleinsäure, Weinsäure, alpha-Aminobuttersäuren, beta- Aminobuttersäuren und gamma-Aminobuttersäuren, Glutathion, Isocitronensäure, cis- und trans-Aconitsäure, Hydroxycitronensäure, Apfelsäure, Nicotinsäure, Benzoesäure, Oxalsäure, Mesoxalsäure, Oxalessigsäure, Bernsteinsäure, Sorbinsäure, Propantricarbonsäure, Crotonsäure, Itaconsäure, Acrylsäure, Methacrylsäure, Mesaconsäure, Phenylessigsäure, Salicylsäure, 4-Hydroxybenzoesäure, Zimtsäure, Mandelsäure, 2- Furancarbonsäure, Acetessigsäure, Glucuronsäure, Gluconsäure, Glucarsäure, Glycerinsäure, Glykolsäure, Buttersäure, Isobuttersäure, Hexansäure, Heptansäure Octansäure, Decansäure, Undecansäure, Dodecansäure, Tetradecansäure, Palmitinsäure, Stearinsäure, Methacrylsäure, Urocansäure, Pyrrolidonsäure, Glutarsäure, Adipinsäure, Pimelinsäure, Suberinsäure, Azelainsäure, Sebacinsäure, Phthalsäure, Terephthalsäure, 2- und 3-Hydroxybenzoesäure, Milchsäure, unter der Voraussetzung, dass Fumarsäure, Malonsäure, Maleinsäure und Weinsäure > 1 Teil Kreatin enthalten,
Alkyl- und Arylsulfonsäuren,
Ester der Phosphorsäuren,
saure Heterocyclen,
Polymere,
Fettsäuren,
anorganische Säuren,
und deren Mischungen. 1. Compound containing creatine, an acid component and / or a complexing agent, characterized in that the ratio of the creatine component to the acid and / or complex component is 1.0 to 10.0: 1 and the Non-creatine component is selected from the series
racemic, D- and L-amino acids and their derivatives,
namely alanine, beta-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, N-methylglycine, hippuric acid (N-benzoylglycine), histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, 4- Hydroxyproline, serine, trytophan, tyrosine, valine, ornithine, 5-hydroxytryptophan, pipecolic acid, alginic acid, 2-, 3- and 4-aminobenzoic acid, taurine, choline,
organic carboxylic acids and their derivatives,
namely formic acid, acetic acid, pantothenic acid, folic acid, biotin, arachidonic acid, carnosine, fumaric acid, malonic acid, maleic acid, tartaric acid, alpha-aminobutyric acids, beta-aminobutyric acids and gamma-aminobutyric acids, glutathione, isocitric acid, cis- and trans-aconitic acid, hydroxy acid Nicotinic acid, benzoic acid, oxalic acid, mesoxalic acid, oxaloacetic acid, succinic acid, sorbic acid, propane tricarboxylic acid, crotonic acid, itaconic acid, acrylic acid, methacrylic acid, mesaconic acid, phenylacetic acid, salicylic acid, 4-hydroxybenzoic acid, cinnamic acid, mandelic acid, 2-furanacetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, Glyceric acid, glycolic acid, butyric acid, isobutyric acid, hexanoic acid, heptanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tetradecanoic acid, palmitic acid, stearic acid, methacrylic acid, urocanoic acid, pyrrolidonic acid, glutaric acid, adipic acid, pimelic acid, suberic acid Acid, sebacic acid, phthalic acid, terephthalic acid, 2- and 3-hydroxybenzoic acid, lactic acid, provided that fumaric acid, malonic acid, maleic acid and tartaric acid contain> 1 part creatine,
Alkyl and aryl sulfonic acids,
Esters of phosphoric acids,
acidic heterocycles,
polymers
fatty acids,
inorganic acids,
and their mixtures.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10208568A DE10208568A1 (en) | 2002-02-27 | 2002-02-27 | Compound containing creatine, an acid component and / or a complexing agent |
AU2003215607A AU2003215607A1 (en) | 2002-02-27 | 2003-02-27 | Compound containing creatine, an acid component and/or a complexing agent |
PCT/EP2003/002042 WO2003071884A1 (en) | 2002-02-27 | 2003-02-27 | Compound containing creatine, an acid component and/or a complexing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10208568A DE10208568A1 (en) | 2002-02-27 | 2002-02-27 | Compound containing creatine, an acid component and / or a complexing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10208568A1 true DE10208568A1 (en) | 2003-09-18 |
Family
ID=27762480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10208568A Withdrawn DE10208568A1 (en) | 2002-02-27 | 2002-02-27 | Compound containing creatine, an acid component and / or a complexing agent |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003215607A1 (en) |
DE (1) | DE10208568A1 (en) |
WO (1) | WO2003071884A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007209231A (en) * | 2006-02-08 | 2007-08-23 | Japan Organo Co Ltd | Creatine-containing food composition |
DE102006033321A1 (en) * | 2006-07-17 | 2008-01-24 | Westfälische Wilhelms-Universität Münster | Medical use of N-phenylpropenoyl amino acid derivatives and related compounds |
CA3024584A1 (en) | 2016-05-25 | 2017-11-30 | TSI Group Ltd. | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules |
KR101996124B1 (en) * | 2017-01-06 | 2019-07-03 | 연세대학교 산학협력단 | Composition comprising Suberic acid or as active ingredients for Preventing or treating muscle disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004240A1 (en) * | 1994-08-04 | 1996-02-15 | Flamma S.P.A. | Hydrosoluble organic salts of creatine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19653225A1 (en) | 1996-12-20 | 1998-06-25 | Sueddeutsche Kalkstickstoff | New creatine pyruvate derivatives from crystallisation in polar solvents |
DE19707694A1 (en) | 1997-02-26 | 1998-08-27 | Sueddeutsche Kalkstickstoff | New stable, water-soluble creatine ascorbate |
US5925378A (en) | 1997-03-31 | 1999-07-20 | Fortress Systems, L.L.C. | Method for enhancing delivery and uniformity of concentration of cellular creatine |
US5994581A (en) * | 1998-03-09 | 1999-11-30 | Amt Labs, Inc. | Carnitine creatinate |
US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
DE19929993C2 (en) | 1999-06-30 | 2001-07-05 | Sueddeutsche Kalkstickstoff | Creatine alpha ketoglutarate, process for its preparation and its use |
US6114379A (en) * | 1999-07-07 | 2000-09-05 | Albion Laboratories, Inc. | Bioavailable chelates of creatine and essential metals |
IT1306186B1 (en) * | 1999-09-03 | 2001-05-30 | Biosalts Srl | NON HYGROSCOPIC SALTS OF ACTIVE INGREDIENTS FOR THERAPEUTIC AND / ONUTRITIONAL ACTIVITIES AND COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION |
US6211407B1 (en) * | 2000-05-03 | 2001-04-03 | Pfanstiehl Laboratories, Inc. | Dicreatine citrate and tricreatine citrate and method of making same |
ITRM20010155A1 (en) * | 2001-03-23 | 2002-09-23 | Biosalts Srl | CREATINE SALT WITH INCREASED NUTRITIONAL AND THERAPEUTIC VALUE AND COMPOSITIONS THAT CONTAIN IT. |
-
2002
- 2002-02-27 DE DE10208568A patent/DE10208568A1/en not_active Withdrawn
-
2003
- 2003-02-27 WO PCT/EP2003/002042 patent/WO2003071884A1/en not_active Application Discontinuation
- 2003-02-27 AU AU2003215607A patent/AU2003215607A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004240A1 (en) * | 1994-08-04 | 1996-02-15 | Flamma S.P.A. | Hydrosoluble organic salts of creatine |
Non-Patent Citations (1)
Title |
---|
Römpp Lexikon Chemie 10. Aufl., Georg Thieme Verlag 2000, Stichwort "Carbonsäure" * |
Also Published As
Publication number | Publication date |
---|---|
WO2003071884A1 (en) | 2003-09-04 |
AU2003215607A1 (en) | 2003-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5863939A (en) | Creatine ascorbates and a method of producing them | |
DE10065478C1 (en) | Creatine / citric acid compound, process for its preparation and use | |
DE3152071C2 (en) | Taurine derivatives, their manufacture and use in medicines | |
DE10208568A1 (en) | Compound containing creatine, an acid component and / or a complexing agent | |
DE2829580C2 (en) | 2-Formylquinoxaline-1,4-dioxide-cyanoacetylhydrazone, process for its preparation and compositions with this compound | |
DE3151534A1 (en) | ORGANIC MATERIALS STABILIZED WITH AMINO REDUCTIONS AS ANTIOXIDANTS | |
DE19929993C2 (en) | Creatine alpha ketoglutarate, process for its preparation and its use | |
DE60200476T2 (en) | CREATINE SALT FOR FOOD AND THERAPEUTIC USES AND COMPOSITIONS CONTAINING THEREOF | |
DE60010896T2 (en) | THERAPEUTIC AND / OR NUTRITIONAL PHYSIOLOGICALLY IMPROVED DERIVATIVES OF ACTIVE INGREDIENTS AND ORAL ADMINISTRATIVE COMPOSITIONS CONTAINING THEM | |
DE3524788A1 (en) | STABLE, INTRAVENOES APPLICABLE, AQUEOUS FAT EMULSION AND A METHOD FOR THE PRODUCTION THEREOF | |
DE60108122T2 (en) | Fumaric acid dip salts containing carnitine and an amino acid, and food and dietary supplements and medicaments containing the same | |
EP1009410B1 (en) | Method for producing stable acetylsalicylic acid solutions | |
EP0190676A1 (en) | Cis-1,3,5-triamino 2,4,6-cyclohexanetriol derivatives, their use, process for their preparation and pharmaceutical preparations containing them | |
DE60008392T2 (en) | NON-HYGROSCOPIC SALTS OF ACTIVE INGREDIENTS THAT HAVE THERAPEUTIC AND / OR NUTRITIONAL PROPERTIES AND ORAL ADMINISTRATIVE COMPOSITIONS CONTAINING THEM | |
DE10064312C2 (en) | Choline pyruvate hydrate, process for its preparation, formulation containing choline pyruvate hydrate and its use | |
DE60115944T2 (en) | SOLID COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND ALKANOYL-L-KARNITINE WITH TAURIN CHLORIDE | |
DE60316732T2 (en) | BASIC SALT OF THIOCTANIC ACID WITH L-CARNITINE | |
EP0538193B1 (en) | Condensed cycloaliphatir-amidino-hydrazon salts as S-adenosylmethionin decarboxylase inhibitors | |
CN101903020B (en) | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | |
DE69820511T2 (en) | Amino acid derivatives and compositions containing them for the inhibition of active oxygen | |
DE2522218A1 (en) | THERAPEUTIC COMPOSITION, METHYLAMINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | |
WO1998038183A1 (en) | Creatine-ascorbates, production process | |
WO2001010828A1 (en) | S-nitroso- and s-nitro-n-acyl-l-cysteine-ester-derivatives as pharmacological substances and medicaments containing said compounds | |
DE69911021T2 (en) | L-CARNITINE AND ALKANOYL-CARNITINE SOLID COMPOSITIONS CONTAINING NON-HYGROSCOPIC ORAL ADMINISTRATION | |
WO2017008902A1 (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8130 | Withdrawal |